Angina Pectoris, Stable, Coronary Artery Disease, Diabetic Peripheral Neuropathy, Stroke, Ischemic
Conditions
Keywords
Qi Deficiency and Blood Stasis Syndrome, Buqitongluo Granule, Traditional Chinese Medicine, Double-Blind, Randomized Controlled Trial
Brief summary
The main purpose of this trial is to evaluate the efficacy and safety of Buqitongluo Granule in treating qi deficiency and blood stasis syndrome, and explore the effect of the improvement of qi deficiency and blood stasis syndrome on the prognosis of diseases.
Detailed description
The BOSS study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The primary hypothesis of this trial is that Buqitongluo Granule will improve the syndrome score of Qi Deficiency and Blood Stasis in convalescence of ischemic stroke, stable angina pectoris of coronary artery disease and diabetic peripheral neuropathy with qi deficiency and blood stasis syndrome. Buqitongluo Granule will be compared to placebo, combined with guidelines-based standard care in patients. During the trial, it is forbidden to use acupuncture, Traditional Chinese Medicine decoction (compound granule), Traditional Chinese Medicine injection, Chinese patent medicine (including external use), external washing of Traditional Chinese Medicine and health product (composition or efficacy similar to the study drug).
Interventions
DRUGBuqitongluo Granule
Buqitongluo Granules were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
DRUGBuqitongluo Granule Placebo
Buqitongluo Granule placeboes were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
OTHERStandard care
Guidelines-based standard care for convalescence of ischemic stroke, stable angina pectoris of coronary artery disease or diabetic peripheral neuropathy.
Sponsors
The Affiliated Hospital of Changchun University of Chinese Medicine
The Affiliated Hospital of Shandong University of Chinese Medicine
Chengdu University of Traditional Chinese Medicine
The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
First Affiliated Hospital of Heilongjiang Chinese Medicine University
Second Affiliated Hospital of Heilongjiang University of Chinese Medicine
The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine
Hunan Academy of Traditional Chinese Medicine Affiliated Hospital
The First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine
Shaanxi Buchang Pharmaceuticals Co., Ltd.
Beijing Chuanglikechuang Medical Technology Development Co., Ltd.
Shanghai Youningwei Biotechnology Co., Ltd.
Wuhan Zhizhi Medical Technology Co., Ltd.
Wuhan Third Hospital
Rizhao Hospital of Traditional Chinese Medicine
The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine
Jiangbin Hospital of Guangxi Zhuang Autonomous Region
Dongzhimen Hospital, Beijing
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
35 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Convalescence of ischemic stroke Inclusion Criteria: * Diagnosis of qi deficiency and blood stasis syndrome * Diagnosis of ischemic stroke * Age ≥ 35 and ≤ 80 years * The interval from the onset to recruitment was 14-30 days * NIHSS score ≥ 4 and ≤ 22 * Patient or legally authorized representative has signed informed consent.
Exclusion criteria
* Confirmed secondary stroke caused by tumor, brain trauma, or hematological diseases by clinical examination; * Other conditions that lead to motor dysfunction (e.g. lameness, osteoarthrosis, rheumatoid arthritis, gouty arthritis), which render the neurological function examination unlikely to be assessed; * Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg), or renal or hepatic insufficiency (hepatic insufficiency is defined as an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value that is 1.5 times the upper limit of normal, renal insufficiency is defined as a serum creatinine concentration value that is over the upper limit of normal); * Other conditions or mental disorders which according to the judgement of researchers that restrict evaluation of mental function or render outcomes or follow-up unlikely to be assessed; * Woman with pregnancy, lactation, or woman who wants to be pregnant in recent; * Patient who is allergic to the study drug or has severe allergic constitution; * Patient with yellow thick slimy tongue coating; * Patient who has been participated in other drug or device clinical trials in recent 3 months. Stable angina pectoris of coronary artery disease Inclusion Criteria: * Diagnosis of qi deficiency and blood stasis syndrome * Diagnosis of stable angina pectoris of coronary artery disease * Age ≥ 35 and ≤ 80 years * Canadian Cardiovascular Society (CCS) Classification of Angina Pectoris classⅠ-Ⅲ * Patient or legally authorized representative has signed informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the syndrome score of Qi Deficiency and Blood Stasis | Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment | The dynamic evaluation will be defined by Evaluation Scale of Qi Deficiency and Blood Stasis Syndrome. The Evaluation Scale of Qi Deficiency and Blood Stasis Syndrome score ranges from 0 (best score) to 51 (worst score). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for convalescence of ischemic stroke | Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment | Including limb numbness, swelling of hands or feet, spontaneous sweating (hemilateral sweating). Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom). |
| Continuous changes of Modified Rankin Scale for convalescence of ischemic stroke | Baseline, at day 42 during treatment, and at 90 days after onset | The Modified Rankin Scale score ranges from 0 (best score) to 6 (worst score). |
| Activities of daily living will be measured by Barthel Index (BI) score for convalescence of ischemic stroke | Baseline, at day 42 during treatment, and at 90 days after onset | The Barthel Index score ranges from 0 (worst score) to 100 (best score). |
| Quality of life will be measured by Short Form 36 (SF-36) Quality of Life Scale for convalescence of ischemic stroke | Baseline, at day 42 during treatment, and at 90 days after onset | The SF-36 quality of life scale is used to monitor change in subject reported functionality, well-being, and overall health status. The score of each part ranges from 0 (worst score) to 100 (best score). |
| Neurological impairment will be evaluated by National Institute of Health Stroke Scale (NIHSS) for convalescence of ischemic stroke | Baseline, at day 14, day 28, day 42 during treatment | The NIHSS score ranges from 0 (best score) to 42 (worst score). |
| Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for stable angina pectoris of coronary artery disease | Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment | Including chest tightness, chest pain, palpitation, fatigue, spontaneous sweating. Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom). |
| Change of the Clinical Scoring System of Toronto (TCSS) for diabetic peripheral neuropathy | Baseline, at day 14, day 28, day 42 during treatment, at day 14 after treatment, and at 90 days after recruitment | TCSS includes a score of neural symptoms, nerve reflex scores and sensory examination. The TCSS score ranges from 0 (best score) to 19 (worst score). |
| Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for diabetic peripheral neuropathy | Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment | Including local pain, limb numbness, paresthesia (e.g. burning sensation, formication, electrical sensation). Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom). |
| Quality of life will be measured by Short Form 36 (SF-36) Quality of Life Scale for stable angina pectoris of coronary artery disease and diabetic peripheral neuropathy | Baseline, at day 42 during treatment, and at 90 days after recruitment | The SF-36 quality of life scale is used to monitor change in subject reported functionality, well-being, and overall health status. The score of each part ranges from 0 (worst score) to 100 (best score). |
| Change of the Seattle Angina Questionnaire (SAQ) Score for stable angina pectoris of coronary artery disease | Baseline, at day 28 during treatment, at day 14 after treatment, and at 90 days after recruitment | The maximum score is 100, and the higher the score, the better the quality of life and the state of body function of patient. |
Countries
China
Contacts
Primary ContactYing Gao, MD
Backup ContactWeidi Liu
Outcome results
None listed